Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.36 |
| ▸ | MPL | P40238 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RHOA | P61586 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018373 | 0.89 | KDM4E (0.36) | NOTUMKDM4EUSP2HPGDNPSR1 | |
| SCHEMBL4169013 | 0.87 | RORC (0.34) | KDM4EHPGDNPSR1HSD17B10RORC | |
| SCHEMBL3941725 | 0.87 | P2RY12 (0.39) | MPLKDM4EUSP2HPGDNPSR1 | |
| SCHEMBL4742022 | 0.86 | OPRK1 (0.39) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL3941379 | 0.85 | P2RY12 (0.41) | KDM4EHPGDHSD17B10LMNAHTT | |
| SCHEMBL4164145 | 0.85 | MPL (0.37) | MPLKDM4EUSP2HPGDNPSR1 | |
| SCHEMBL4741483 | 0.85 | OPRK1 (0.38) | KDM4EUSP2HPGDNPSR1HSD17B10 | |
| SCHEMBL3934546 | 0.84 | P2RX7 (0.32) | NOTUMMPLKDM4EUSP2HPGD | |
| SCHEMBL4179572 | 0.83 | P2RX7 (0.37) | MPLP2RX7 | |
| SCHEMBL4170288 | 0.83 | P2RX7 (0.38) | MPLKDM4EUSP2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009011627-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018166-A1 | New Pyridine Analogues X 161 | P2RY12, P2RY11, P2RY1 | NOTUM 4683/4885MPL 45/4885KDM4E 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.